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Clinical Investigation
A Filtration System That Greatly Reduces Aluminum in Calcium 
Gluconate Injection, USP Used to Prepare Parenteral Nutrition 
Solutions
Robert A. Yokel, PhD,1,2, Wesley R. Harris, PhD,2,3 Christopher D. Spilling, PhD,2,3 Vasiliy P. Abramov, MS,4 
Jason M. Lone, MEng,4 and Robert J. Kuhn, PharmD2,5
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, 
2ALKYMOS Inc, Lexington, Kentucky, 3Department of Chemistry and Biochemistry, University of Missouri, St Louis, 
Missouri, 4CreoSalus, Louisville, Kentucky, 5Department of Pharmacy Practice and Science, College of Pharmacy, 
University of Kentucky, Lexington, Kentucky
OBJECTIVE: The study objective was to reduce aluminum (Al) in Calcium Gluconate Injection, US Pharma-
copeia (USP) used in the preparation of parenteral nutrition (PN) solutions.
METHODS: A flow-through filter containing an immobilized chelator that complexes Al from Calcium 
Gluconate Injection, USP as it flows through the filter was designed, refined by design modifications, and 
extensively tested. When a small-volume parenteral vial containing 100 mL of Calcium Gluconate Injection, 
USP is connected on the inlet side of the filter, and the outlet side is connected to an evacuated receiving 
vial, the filtered solution is drawn into the receiving vial. This constitutes a complete system to remove Al 
from Calcium Gluconate Injection, USP.
RESULTS: The extent of Al removal is flow rate dependent. At a flow rate of 1 mL/min approximately 85% 
of the Al was removed from calcium gluconate solution. PN solutions have been reported to deliver 15 to 
23 mcg/kg/day Al to neonates. Given that Calcium Gluconate Injection, USP provides 85% of the Al in neo-
natal PN solutions, removal of 85% of the Al from this source was calculated to reduce Al delivered to most 
neonates to <5 mcg/kg/day.
CONCLUSIONS: A point-of-use, self-contained, single-use, disposable, Al-complexing filter has been cre-
ated. It was calculated to reduce Al delivered in PN solutions by 72%, resulting in daily Al delivery below the 
level that results in Al accumulation associated with central nervous system and bone toxicity to all but the 
smallest (<1 kg) infants.
INDEX TERMS: aluminum, calcium gluconate, parenteral nutrition
J Pediatr Pharmacol Ther 2014;19(3):189–195
INTRODUCTION
Aluminum (Al) is a contaminant of small- and 
large-volume parenteral (SVP and LVP) solu-
tions used to compound parenteral nutrition 
(PN) solutions. It produces no beneficial effects 
in the human but has the potential to produce 
toxicity to the brain, skeletal system, liver, and 
erythropoietic system. Premature neonates are 
the population at greatest risk for Al toxicity 
because of their immature renal function (the 
primary route of Al elimination). A standard 
PN solution that delivered 45 mcg/kg/day Al 
was given to premature neonates for about 10 
days and resulted in significant reduction in the 
Bayley Mental Development Index score at age 
18 months compared with infants who received 
approximately 15% as much Al.1 A follow-up 
study a decade later showed the children who 
received the PN solution that delivered 45 mcg/
kg/day Al had less lumbar spine bone mineral 
content than those who received 15% as much 
Al.2 Al may contribute to the vitamin D–resistant 
rickets seen in neonates given PN.3,4 Al in PN 
solution may also contribute to cholestasis.5,6 A 
microcytic, hypochromic anemia that appears in 
adult dialysis patients7 correlates with plasma 
Al concentration.8 This has been associated with 
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elevated Al in pediatric patients,9 but the associa-
tion of anemia and Al exposure has evidently not 
been investigated in neonates.
The amount of Al given to neonates in PN solu-
tions was estimated10,11 based on the maximum 
Al content stated on the product label, which 
ranged up to 12,500 mcg/L. Such calculations do 
not document the actual amount of Al delivered 
to neonates by PN, given that the product’s Al 
concentration may be considerably less than the 
maximum stated on its label.
Al delivered to 10 neonatal patients weighing 
1.5 to 2.5 kg was determined by quantifying 
the Al in prepared PN solutions. This showed 
a mean ± SD of 15.2 ± 8.0 mcg/kg/day.12 Based 
on Al eliminated in the urine, 56% of the intake 
was retained by these infants. Similarly, the mea-
sured Al in PN solutions given to 40 neonates 
revealed a mean daily delivery ranging from 23 
mcg/kg in patients weighing <1 kg to 15 mcg/
kg in 4- to 6-kg patients.13 This level of Al deliv-
ery is well above the 4 to 5 mcg/kg/day Al load 
that results in Al accumulation associated with 
central nervous system and bone toxicity noted 
in the Food and Drug Administration’s (FDA’s) 
labeling requirement that addresses Al in SVP 
and LVP solutions.14
The Al concentration of PN components and 
prepared PN solutions is not routinely quanti-
fied before their use. As a result, the amount 
of Al given to patients is not routinely known. 
The main source of the Al in PN solutions is 
Calcium Gluconate Injection, US Pharmacopeia 
(USP), which was shown to contribute 78% to 
89% of the Al in PN solutions.15–18 Al increases 
over time in calcium gluconate packaged in 
glass vials because of the Al complexing ability 
of gluconate, which leaches Al from the glass 
storage container.19,20 The clinical problem of Al 
contamination in components used to compound 
PN solutions has been recognized for nearly 30 
years. It was recently reviewed21–24 and presented 
at an international aluminum conference.25
To reduce the amount of Al delivered to 
neonates, it was suggested to use component 
SVP and LVP solutions that have the smallest 
maximum Al concentration according to the 
product label, and to minimize the shelf life of 
calcium gluconate.10,23,26 Even with use of these 
approaches it is currently not possible to bring 
the Al delivered to neonates by PN to less than 
4 to 5 mcg/kg/day.21,23 To address this problem 
we developed a filter that removes most of the Al 
from Calcium Gluconate Injection, USP.
MATERIALS AND METHODS
To reduce the amount of Al delivered in PN 
solutions, we considered the steps in the PN 
preparation process amenable to Al removal, 
the preferable method of Al removal, and the ap-
plication of that method. Selective removal of Al 
from the compounded PN solution was deemed 
not possible because there were no known meth-
ods to remove Al without also removing essential 
trace metals, such as iron and copper. The focus 
was then on Al removal from its primary source, 
Calcium Gluconate Injection, USP. Removal of 
Al by complexation to an immobilized chela-
tor (resin), so that the chelator did not enter the 
calcium gluconate solution, was selected as the 
most practical approach. Consideration of both 
Al complexing ability by the chelator and ease of 
synthesis suggested incorporation of hydroxamic 
acid, the functional moiety of desferrioxamine 
(deferoxamine), used clinically to reduce Al ac-
cumulation and toxicity.27,28
The ligand exchange rate for Al is rather slow,29 
and the rate of calcium gluconate addition to PN 
solutions as they are being prepared by commer-
cial compounders is very high. Therefore, it was 
concluded that Al extraction efficiency would 
probably be very low if the resin were exposed to 
the Al-contaminated calcium gluconate solution 
flowing at this high rate. This was confirmed by 
preliminary studies using a simple flow-through 
cartridge containing the resin that showed an 
inverse relationship between flow rate and Al 
extraction efficiency. This dictated a point of ap-
plication that was off-line from the preparation of 
PN solution (not used in-line between the calcium 
gluconate source and the bag containing the PN 
being prepared). We investigated several con-
cepts. The use of a recirculating peristaltic/roller 
or syringe pump to push the calcium gluconate 
through a cartridge containing the resin had the 
disadvantages of the required equipment, the 
requirement to validate electrical/power compli-
ance, the need for the person using the pump to 
select the proper flow rate, and the need for the 
pump to automatically stop at the end of filtration. 
Space constraints in the laminar flow hood were 
also of major concern with this approach. A “tea 
bag” approach in which the resin would be con-
RA Yokel, et al
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tained in a semipermeable membrane (bag) was 
found to benefit from agitation for good efficiency. 
However, this would require auxiliary equipment, 
a bag in a bottle is not standard practice in the 
hospital’s IV/PN preparation room, and there was 
concern the bag may occlude the outlet when the 
calcium gluconate solution was withdrawn. We 
investigated loose resin beads in a vial that would 
receive the calcium gluconate. The resin beads 
would have to be retained by a membrane. We 
considered that the end users might be concerned 
that the membrane did not retain all of the beads. 
We found greater Al extraction with the resin in a 
flow-through cartridge compared with a suspen-
sion of the resin in the calcium gluconate.
As an alternative to pushing the calcium glu-
conate through the resin, we investigated using 
partial vacuum to pull it through a cartridge con-
taining the resin. This was achieved using a par-
tially evacuated receiving vial to pull the calcium 
gluconate solution through a cartridge containing 
the resin, and a flow restrictor to control the fluid 
flow rate (the ALKYMOS ACE filter, ALKYMOS 
Inc, Lexington, KY). This approach requires no ad-
ditional equipment. A flow rate of 1 mL/min was 
selected as a compromise between the increased 
Al extraction efficiency achieved with longer 
extraction time and the resultant duration of the 
extraction. This flow rate requires 100 minutes to 
remove Al from 100 mL of calcium gluconate. This 
approach was tested with commercial Calcium 
Gluconate Injection, USP, 100-mL vials (from 
APP Pharmaceuticals LLC, Schaumburg, IL) and 
Calcium Gluconate Injection, USP to which ad-
ditional Al was added to approach the maximum 
Al concentration of some Calcium Gluconate 
Injection, USP products (12,500 mcg/L). This 
was accomplished by adding Al (as the nitrate) to 
give higher initial Al concentrations of 8000 and 
11,500 mcg/L and allowing equilibration for >1 
week. The Al concentration was quantified using 
inductively coupled plasma mass spectrometry 
(Agilent 7500cx, Santa Clara, CA).
The above experiments were conducted with 
non–gamma-irradiated filters. In addition, 3 
filters were exposed to 25-kGy and 3 filters to 50-
kGy gamma irradiation, and Al and calcium con-
centrations before and after filtration of Calcium 
Gluconate Injection, USP were determined using 
inductively coupled plasma mass spectrometry. 
Results were compared to a standard curve cre-
ated from an Ultra Scientific (N. Kingstown, RI) 
Analytical Solutions multielement standard. A 
PlasmaCAL multielement calibration standard 
(SCP Science, Champlain, NY) was used to pre-
pare the intercalibration verification standard. 
Scandium was added as the internal standard to 
all samples and standards for the Al and calcium 
analyses.
Using the extent of Al extraction from Cal-
cium Gluconate Injection, USP by the gamma-
sterilized ALKYMOS ACE filters, we calculated 
the reduction in total Al exposure expected in 
patients receiving PN solutions, assuming that 
85% (based on the 78%-89% described in the 
introduction15–18) of the Al in PN solutions is 
derived from Calcium Gluconate Injection, USP. 
Poole et al13 measured the Al delivered to 40 neo-
nates receiving PN. The calculated Al exposure 
reduction was applied to the results of Poole et 
al13 to predict the Al load that would be delivered 
to neonates if the ALKYMOS ACE filter was used.
RESULTS
The commercial Calcium Gluconate Injection, 
USP contained 3200 to 4500 mcg/L Al. More than 
90% of the Al from 100 mL of this product was 
removed by the ALKYMOS ACE filter (Figure 1). 
When the Al concentration of Calcium Gluconate 
Injection, USP was 8000 or 11,500 mcg/L (after 
addition of Al nitrate), the filter still removed 
≥85% of the Al (Figure 2). Al removal rates were 
87% and 84% by 25- and 50-kGy gamma-steril-
ized filters, respectively. The calcium concentra-
Figure 1. Percentage of aluminum removed from com-
mercial Calcium Gluconate Injection, USP by the ALKYMOS 
ACE filter. Results are from 4 separate experiments, each 
conducted with 2 to 4 replicates.
Filter System to Remove Al From Calcium Gluconate
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tions after filtration through filters exposed to 
25- and 50-kGy gamma irradiation were 100% 
and 101%, respectively. Assuming removal of 
85% of the Al from calcium gluconate, which is 
contributing 85% of the Al in prepared PN solu-
tions,15–18 we calculate that the ALKYMOS ACE 
filter should reduce Al in the PN solution by 72%.
Two examples illustrate the amount of Al that 
can be removed using the ALKYMOS ACE filter. 
Among infants weighing between 1 and 6 kg 
in the Poole et al13 study, those weighing 1 to 2 
kg were exposed to the highest average Al load 
(17.62 mcg/kg/day). Using the ALKYMOS ACE 
filter, which should reduce Al by 72%, the daily 
Al exposure would be 4.9 mcg/kg/day (Figure 
3). For infants weighing less than 1 kg, Poole et 
al13 reported Al exposure of 23.11 mcg/kg/day. 
After calcium gluconate filtration, Al load should 
be reduced to 6.4 mcg/kg/day. So this filtration 
system will allow for daily Al delivery below the 
level that results in Al accumulation associated 
with central nervous system and bone toxicity, 
except for those infants who weigh less than 1 
kg or who have an extraordinarily high calcium 
requirement.
DISCUSSION
Several concepts were considered and inves-
tigated to remove Al from Calcium Gluconate 
Injection, USP using an immobilized chelator 
(resin). Numerous prototypes were tested to de-
termine the influence of flow rate, concept, and 
calcium gluconate Al concentration on Al extrac-
tion. A filter containing the resin through which 
Calcium Gluconate Injection, USP was drawn 
showed the greatest reduction of Al, >90%. Filters 
sterilized by gamma irradiation removed 85% of 
the Al. This process required no auxiliary equip-
ment and was completed in less than 2 hours.
This approach has the potential to address the 
long-standing concern regarding the amount 
of Al delivered in PN solutions, particularly to 
premature neonates. This approach focuses on re-
duction of Al in the primary source contributing 
Al to PN solutions, Calcium Gluconate Injection, 
USP. Premature neonates are at greatest risk of 
Al accumulation and potential toxicity because of 
their incompletely developed renal function and 
high calcium requirement. This long-recognized 
problem has not been adequately resolved. In 
1986 an FDA Advisory Panel recommended 
that Al be eliminated from components of PN 
solutions.30 After three open meetings to discuss 
this issue,31 the FDA published in 1990 a Notice 
of Intent to establish a labeling requirement. In 
1998, the FDA proposed a rule, “Aluminum in 
Large and Small Volume Parenterals Used in 
Total Parenteral Nutrition,” to amend its label-
Figure 2. Percentage of aluminum (Al) removed from com-
mercial Calcium Gluconate Injection, USP, to which Al was 
added, by the ALKYMOS ACE filter. Dashed vertical line is 
maximum commercial product Al concentration. Results 
are the 2 replicates at each concentration.
Figure 3. Predicted aluminum (Al) in PN solutions pre-
pared with ALKYMOS ACE–filtered calcium gluconate. Al 
delivered daily to patients by parenteral nutrition (PN) 
from Poole et al13 (black filled histograms) and the cal-
culated daily Al load, assuming that calcium gluconate 
contributes 85% of the total Al to PN and that 85% of the 
Al from calcium gluconate is removed by filtration through 
the ALKYMOS ACE filter (open histograms), compared with 
the 5 mcg/kg/day Food and Drug Administration guideline 
(horizontal dashed line).
RA Yokel, et al
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ing requirement. The rule noted that “levels of 
aluminum at greater than 4 to 5 mcg/kg/day 
accumulate with central nervous system and 
bone toxicity,”32 set an upper limit of 25 mcg/L 
(0.90 μM) of Al in LVPs used in PN, and required 
a statement of the maximum Al concentration in 
SVPs at expiry. The information was intended 
to allow health care professionals to calculate a 
patient’s exposure to Al when receiving PN and 
to take actions that limit intake in patients sus-
ceptible to Al toxicity. After 3 delays, the rule was 
implemented on July 26, 2004, as 21CFR(201.323), 
and was updated in 2012.14 The delays were due 
to concerns expressed by SVP manufacturers that 
they were probably not meeting the limit and that 
it may be difficult to do so.33 The Al content of 
PN solutions still exceeds the FDA safe level.12,13 
Furthermore, the Al content of PN solutions 
cannot be accurately determined by calculation 
based on the maximum Al content of components 
used to compound the PN solution.13 Calcium 
gluconate solution Al content increases over 
time when it is stored in a glass vial, because of 
leaching of Al from the glass.19 This increase was 
observed during conduct of the present study. 
Therefore, a statement of Al content in Calcium 
Gluconate Injection, USP at the time of release, 
as suggested,26 would not provide information 
about the Al concentration at the time of use. 
Because it is not practical to routinely quantify 
Al in prepared PN solutions, or even Calcium 
Gluconate Injection, USP prior to PN administra-
tion, health care professionals are delivering an 
A B C
Figure 4. (A) A schematic diagram of the ALKYMOS ACE filter. (B) The ALKYMOS ACE filter system and a commercial 
vial of Calcium Gluconate Injection, USP during filtration of the calcium gluconate solution. (C) The ALKYMOS ACE filter 
system and a commercial vial of Calcium Gluconate Injection, USP during filtration, to illustrate the space requirement 
for this process.
unknown amount of Al to their patients.
It was suggested to add desferrioxamine to PN 
solutions to complex the Al as aluminoxamine, 
which would presumably be eliminated in the 
urine, assuming adequate renal function to do 
so.34 However, this would potentially expose the 
patient to desferrioxamine, which has consider-
able adverse effects. Desferrioxamine complexes 
trivalent metals and forms a stronger coordina-
tion bond with iron than Al,35 potentially reduc-
ing iron and other essential metals. The present 
approach uses the same functional group as 
desferrioxamine (hydroxamic acid) to remove 
the Al before it enters the PN solution.
CONCLUSIONS
The ACE filter, developed by ALKYMOS, 
draws Calcium Gluconate Injection, USP from 
the commercial SVP vial through a cartridge con-
taining hydroxamic acid–containing resin into 
an evacuated receiving vial. The low-Al calcium 
gluconate solution from the receiving vial would 
then be used to prepare PN solutions. The Al 
removal process is conducted off-line and can be 
initiated prior to PN preparation so that it does 
not interfere with or have a direct impact on PN 
preparation, and the filtered calcium gluconate 
is ready to use when PN compounding begins. 
This pharmaceutical compounding process takes 
2 hours. Multiple vials can be filtered simultane-
ously. The space required is quite small and is 
above the working counter of the laminar flow 
Filter System to Remove Al From Calcium Gluconate
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hood, so that multiple filtration systems could 
be operating while other activities are ongoing 
in the laminar flow hood (Figure 4). The filtra-
tion process should be initiated at the onset of 
PN preparation setup so that the filtered calcium 
gluconate solution will be available 2 hours later 
when PN preparation begins.
The ALKYMOS ACE filter is a point-of-use, 
self-contained, single-use, disposable, Al-com-
plexing filter. It has been shown to remove 85% 
of the Al from Calcium Gluconate Injection, USP. 
It should reduce Al delivered in PN solutions 
by 72%, resulting in daily Al delivery below the 
level considered toxic to all but the smallest (<1 
kg) infants. This filter system fills a void because 
currently there are no commercially available op-
tions to reduce Al for the pharmacist to employ 
to extract Al from pediatric and neonatal PN.
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